The future of anti-body based drugs: Where are the opportunities and what does the future hold? This is a free 16 page e report, available here.

This report

  • Provides an overview of the monoclonal antibody (mAbs) industry: market value, key antibody-based drug players, opportunities and the future for the sector
  • Explore what’s next for antibody-based drugs and where the opportunity is coming from
  • Includes an interview with Bio-Rad’s John Cardone, who shares expertise on the future of antibody-based drug discovery
  • Shares significant future trends for the therapeutic antibody market

Key insights:

  • The global mAb market size was valued at $185.50 billion in 2021
  • Biopharmas originating in China will likely have greater influence on the industry by 2028
  • The lessons learned from mAb development for SARS-CoV-2 will likely provide an important platform for the scientific community
  • With over 10 biosimilars approved, Argentina and Brazil have the most biosimilar monoclonal antibodies approved in Latin America

    Sponsored by 



Download the e-report